Everything drug pricing and policy, every day
Plus Blue Shield of California’s CEO muses on GLP-1 subscription models
Plus a look at whether access in Canada is being compromised in the era of MFN
And a German-government-backed MFN study exposes a contradiction at the heart of the U.S. approach to international prices
Plus links on the politics of MFN deals and the contribution of 340B to health-spending growth
And why CVS’ plan to split is unlikely to mollify critics
Plus CVS unveils plan to spin off its retail pharmacy business amidst policy pressures